Skip to main content

Table 1 Age-specific prevalence of high-risk HPV and precancer among women with unknown HIV status

From: Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage

Age at screening (years) No. of women screened in the age group No. of HPV-positive (% of women screened) (95% CI) Colposcopy attendance among HPV-positive Histopathology resultsb (% of women attending colposcopyc) (95% CI) Yield of the screening effortb (% of total women screened)
CIN2+ CIN3+ CIN2+ CIN3+
30–34 2553 476 (18.6%) (17.2–20.2%) 393 (82.6%) 26 (6.6%) (4.4–9.6%) 14 (3.6%) (2.0–5.9%) 1.0% 0.5%
35–39 2646 411 (15.5%) (14.2–17.0%) 354 (86.1%) 18 (5.1%) (3.0–7.9%) 10 (2.8%) (1.4–5.1%) 0.7% 0.4%
40–44 2282 351 (15.4%) (13.9–16.9%) 309 (88.0%) 12 (3.9%) (2.0–6.7%) 5 (1.6%) (0.5–3.7%) 0.5% 0.2%
45–49 1479 213 (14.4%) (12.7–16.3%) 194 (91.1%) 15 (7.7%) (4.4–12.4%) 7 (3.6%) (1.5–7.3%) 1.0% 0.5%
Total 8960a 1451 (16.2%) (15.4–17.0%) 1250 (86.1%) 71 (5.7%) (4.5–7.1%) 36 (2.9%) (2.0–4.0%) 0.8% 0.4%
  1. aNot including four women with missing data on age
  2. bCIN2+ and CIN3+ include a total of four cases of squamous cell carcinoma (two of them were in 49-year old women, one in a 47-year old woman, and one in a 33-year old woman; all four cases were diagnosed on biopsy). We also presumptively included five women with OncoE6 HPV 16 positivity because of the known high positive predictive value of the biomarker (Three of the five had confirmed CIN2+; in two LLETZ was recommended and is still incomplete)
  3. cHistopathology report was not completed for four participants due to COVID-19 pandemic spread and lockdown. These four participants were excluded from the denominator